Based on the finding that reovirus treatment induces PD-L1 expression, a Phase I trial of intravenous reovirus and pembrolizumab in addition to chemotherapy with eleven patients suffering from pancreatic cancer was initiated. This evidence concerns the gene CD274 and pancreatic neoplasm.